Surrogate Endpoints Acceptable in AML Trials, Says FDA
In the case of drugs used for newly diagnosed acute myeloid leukemia (AML), surrogate endpoints have been validated, says the US Food and Drug Administration.
United States Courtney Dinardo Kelly Norsworthy University Of Texas Md Anderson Cancer Center University Of Colorado Drug Administration
Source: medscape.com